Jonathan Bowman, MD
Vascular Surgery · Darien, CTNPI 1104851294
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (54.6%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Angiodynamics, Inc. at 55.2% of the total. Among vascular surgery clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 234 payments — averaging $228.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$30K
- Philips North America LLC$7K
- Medtronic$5K
- Inari Medical, Inc.$3K
- Stryker$3K
- Bard Peripheral Vascular, Inc.$921
- plus $4K from 28 others
Across 51 payments — averaging $4514.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cook Research Incorporated$116K
- Endologix LLC$83K
- Trireme Medical LLC$28K
- Humacyte Global, Inc.$3K
What the payments were for
- Consulting fees$4,3508%
- Speaking & faculty fees$8,30016%
- Travel & lodging$1,0372%
- Food & beverage$10,57320%
- Other$29,22855%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 12 | $29,527 |
| Philips North America LLC | 15 | $7,307 |
| Medtronic(2 entities) | 61 | $4,617 |
| Inari Medical, Inc. | 22 | $3,435 |
| Stryker | 10 | $3,369 |
| Bard Peripheral Vascular, Inc. | 17 | $921 |
| Cook Medical LLC | 12 | $694 |
| KCI USA, Inc. | 1 | $600 |
| Boston Scientific | 16 | $454 |
| BD | 1 | $450 |
| Johnson & Johnson(2 entities) | 16 | $328 |
| Silk Road Medical, Inc. | 4 | $323 |
| Endologix LLC | 6 | $308 |
| Lemaitre Vascular, Inc. | 5 | $300 |
| E.r. Squibb & Sons, L.L.C. | 10 | $206 |
| Lifenet Health | 1 | $161 |
| Tactile Systems Technology Inc | 6 | $89 |
| Cardiovascular Systems Inc. | 2 | $67 |
| Merit Medical Systems Inc | 1 | $43 |
| Pfizer | 2 | $29 |
| Covidien LP | 1 | $26 |
| Reprise Biomedical, Inc. | 1 | $25 |
| Abbott | 1 | $25 |
| W. L. Gore & Associates, Inc. | 1 | $23 |
| Penumbra, Inc. | 1 | $21 |
| Asahi Intecc USA, Inc. | 1 | $21 |
| Solventum Corporation | 1 | $19 |
| Bolton Medical Inc | 1 | $19 |
| Smith+Nephew | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Cordis US CORP. | 1 | $15 |
| Biocompatibles, Inc. | 1 | $14 |
| Bsn Medical Inc | 1 | $12 |
| Reflow Medical Inc | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$29,228
- FLOWTRIEVER CATHETER, S$5,757
- CT THROMBECTOMY SYSTEM KIT$5,757
- IGT D Peripheral$4,800
- ENDURANT IIS$2,503
- Spectranetics Undiv$2,000
- ELLIPSYS VASCULAR ACCESS SYSTEM$819
- PREVENA$600
- ENROUTE Transcarotid Neuroprotection System$376
- Crosser iQ$271
- ROSEN$255
- ENROUTE Transcarotid Stent System$220
- ENHANCE Transcarotid Peripheral Access Kit$220
- ENROUTE 0.014 Guidewire$220
- TheraGenesis Wound Matrix$161
- Zilver PTX$155
- Fluency Endovascular Stent Graft$121
- RESTOREFLO$112
- Veradius Neo$109
- ARTEGRAFT VASCULAR GRAFT$108
How this compares
$53,487 in reported general payments places this provider in the 90th percentile of 82 vascular surgery providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 56 | $52,115 |
| XareltoRivaroxaban | 16 | $17,464 |
| ClopidogrelClopidogrel Bisulfate | 98 | $1,163 |
| Cilostazol | 12 | $313 |
| Gabapentin | 11 | $299 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 16 | $97 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $29 | $52,11556 claims |
| Johnson & JohnsonXarelto | $328 | $17,46416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 82 vascular surgery providers in Connecticut.
Other vascular surgery in Darien
- Paul GagneDarien$766K
- Timothy ManoniDarien$46K
- Taras KucherDarien$38K
- Ben MarsanDarien$36K
- Chong LiDarien$13K
- Benjamin ChandlerDarien$8K
- Andrew LazarDarien$4K
- Uwe FischerNew London$941K
- Naiem NassiriNew Haven$348K
- Lee GoldsteinStratford$272K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.